In the latest trading session, Celgene (CELG - Free Report) closed at $86.80, marking a -0.45% move from the previous day. The stock lagged the S&P 500's daily gain of 0.04%. Meanwhile, the Dow gained 0.11%, and the Nasdaq, a tech-heavy index, lost 0.23%.
Prior to today's trading, shares of the biotechnology company had lost 5.91% over the past month. This has lagged the Medical sector's gain of 2.85% and the S&P 500's gain of 2.16% in that time.
CELG will be looking to display strength as it nears its next earnings release, which is expected to be October 25, 2018. In that report, analysts expect CELG to post earnings of $2.22 per share. This would mark year-over-year growth of 16.23%. Meanwhile, our latest consensus estimate is calling for revenue of $3.81 billion, up 15.8% from the prior-year quarter.
For the full year, our Zacks Consensus Estimates are projecting earnings of $8.76 per share and revenue of $15.11 billion, which would represent changes of +17.74% and +16.27%, respectively, from the prior year.
Investors should also note any recent changes to analyst estimates for CELG. These revisions help to show the ever-changing nature of near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Within the past 30 days, our consensus EPS projection remained stagnant. CELG currently has a Zacks Rank of #2 (Buy).
Digging into valuation, CELG currently has a Forward P/E ratio of 9.95. This represents a discount compared to its industry's average Forward P/E of 28.91.
Investors should also note that CELG has a PEG ratio of 0.46 right now. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. The Medical - Biomedical and Genetics industry currently had an average PEG ratio of 1.79 as of yesterday's close.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 97, putting it in the top 38% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks. Com to follow all of these stock-moving metrics, and more, in the coming trading sessions.